Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

This publication has 63 references indexed in Scilit:

• Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary
  Endocrine Practice, 2017
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
  New England Journal of Medicine, 2016
• The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
  Diabetes Care, 2016
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
  Diabetes Care, 2014
• Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
  Diabetes Care, 2013
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
  Diabetes, 2009
• 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
  New England Journal of Medicine, 2008
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  The Lancet, 2005
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
  The Lancet, 1998